Drugs for Early Myoclonic Encephalopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 23)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Liver Extracts |
|
Phase 4 |
|
|
|
2 |
|
Ethanol |
Approved |
Phase 3 |
|
64-17-5 |
702 |
Synonyms:
[CH2Me(OH)]
[OEtH]
1-Hydroxyethane
ABLYSINOL
Absolute alcohol
Absolute ethanol
Absolute ethyl alcohol
Aethanol
Aethylalkohol
Alcare hand degermer
Alcohol
Alcohol (ethyl)
Alcohol anhydrous
Alcohol denatured
ALCOHOL DETERMINATION--ALCOHOL
Alcohol etilico
Alcohol etílico
Alcohol, absolute
Alcohol, Dehydrated
Alcohol, denatured
ALCOHOL, DILUTED
Alcohol, ethyl
Alcohol, grain
ALCOHOL, RUBBING
Alcohols
Alcool ethylique
Alcool éthylique
Alcool etilico
Algrain
Alkohol
Alkoholu etylowego
Aminoethanol
Anhydrol
Anhydrous alcohol
Anhydrous ethanol
Äthanol
Äthylalkohol
B3324
Beta-Aminoethanol
Beta-Aminoethyl Alcohol
Beta-Ethanolamine
Beta-Hydroxyethylamine
C2H5OH
Caswell No. 426
Colamine
Cologne spirit
Cologne spirits
Dehydrated alcohol
Dehydrated ethanol
Denatured alcohol
Denatured Alcohol Cd-10
Denatured Alcohol Cd-5
Denatured Alcohol Cd-5a
Denatured Alcohol Sd-1
Denatured Alcohol Sd-13a
Denatured Alcohol Sd-17
Denatured Alcohol Sd-23a
Denatured Alcohol Sd-28
Denatured Alcohol Sd-30
Denatured Alcohol Sd-39b
Denatured Alcohol Sd-39c
Denatured Alcohol Sd-3a
Denatured Alcohol Sd-40m
Denatured ethanol
Desinfektol el
Diluted alcohol
Distilled spirits
DRINKING ALCOHOL
E1510
Envision Conditioner Pdd 9020
ETA
Etanol
|
Etanolo
ETHANOL
éthanol
Ethanol 200 proof
Ethanol Absolute
Ethanol Absolute Bp
Ethanol Anhydrous
Ethanol Extra Pure
Ethanol solution
Ethanol, Silent Spirit
Ethicap
Ethyl alc
Ethyl alcohol
Ethyl Alcohol & Water, 10%
Ethyl Alcohol & Water, 20%
Ethyl Alcohol & Water, 30%
Ethyl Alcohol & Water, 40%
Ethyl Alcohol & Water, 5%
Ethyl Alcohol & Water, 50%
Ethyl Alcohol & Water, 60%
Ethyl Alcohol & Water, 70%
Ethyl Alcohol & Water, 80%
Ethyl Alcohol & Water, 95%
Ethyl Alcohol & Water, 96%
Ethyl alcohol anhydrous
Ethyl alcohol in alcoholic beverages
Ethyl alcohol usp
Ethyl Alcohol, Anhydrous
Ethyl Alcohol, Denatured
Ethyl hydrate
Ethyl hydroxide
Ethylol
Ethylolamine
EtOH
FEMA NO. 2419
Fermentation alcohol
Glycinol
Grain alcohol
Hinetoless
HSDB 531
Hydroxyethane
Infinity pure
Jaysol
Jaysol S
Lux
METHYLATED MINERAL
Methylated Spirit Mineralised
Methylcarbinol
Molasses alcohol
NCI-C03134
NSC-85228
PM-6193-200
Potato alcohol
Punctilious ethyl alcohol
Pyro
Reagent Alcohol
Silent spirit
SPIRIGEL
Spirit
Spirits OF wine
Spiritus vini
Spirt
SURG
Synasol
Tecsol
Tecsol C
Thanol
Thiofaco M-50
Undenatured ethanol
USAF EK-1597
VODKA
|
|
3 |
|
Strawberry |
Approved |
Phase 3 |
|
|
|
4 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
5 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
6 |
|
Fenfluramine |
Approved, Illicit, Investigational, Withdrawn |
Phase 3 |
|
458-24-2 |
3337 |
Synonyms:
(+-)-Fenfluramine
(±)-fenfluramine
1-(m-Trifluoromethyl-phenyl)-2-ethylaminopropane
2-Ethylamino-1-(3-trifluoromethylphenyl)propane
3-(Trifluoromethyl)-N-ethyl-alpha-methylphenethylamine
3-(Trifluoromethyl)-N-ethyl-a-methylphenethylamine
3-(Trifluoromethyl)-N-ethyl-α-methylphenethylamine
Adifax®|Fintepla®|Pondimin®|ZX008
DL-Fenfluramine
Ethyl-[1-methyl-2-(3-trifluoromethyl-phenyl)-ethyl]-amine
Fenfluramina
Fenfluramine
Fenfluramine hydrochloride
Fenfluramine hydrochloride, (+-)-isomer
Fenfluramine hydrochloride, R isomer
|
Fenfluramine hydrochloride, R-isomer
Fenfluramine, (+-)-isomer
Fenfluramine, R isomer
Fenfluramine, R-isomer
Fenfluraminum
Hydrochloride, fenfluramine
Isomeride
N-Ethyl-1-(3-(trifluoromethyl)phenyl)propan-2-amine
N-Ethyl-alpha-methyl-3-trifluoromethylphenethylamine
N-Ethyl-a-methyl-3-trifluoromethylphenethylamine
N-Ethyl-α-methyl-3-trifluoromethylphenethylamine
Ponderax
Pondimin
Robins brand OF fenfluramine hydrochloride
|
|
7 |
|
Zonisamide |
Approved, Investigational |
Phase 3 |
|
68291-97-4 |
5734 |
Synonyms:
1,2-Benzisoxazole-3-methanesulfonamide
1,2-Benzisoxazole-3-methanesulphonamide
3 Sulfamoylmethyl 1,2 benzisoxazole
3-(Sulfamoylmethyl)-1,2-benzisoxazole
3-(Sulphamoylmethyl)-1,2-benzisoxazole
3-Sulfamoylmethyl-1,2-benzisoxazole
AD-810
AD-810|CI-912|PD-110843|Zonegran®
Benzo[D]isoxazol-3-yl-methanesulfonamide
Benzo[D]isoxazol-3-yl-methanesulphonamide
CI-912
Elan brand OF zonisamide
|
Exceglan
Excegram
Excegran
PD-110843
Zonegran
Zonisamida
Zonisamida [Spanish]
Zonisamide
Zonisamide monosodium
Zonisamidum
Zonisamidum [Latin]
|
|
8 |
|
Serotonin Uptake Inhibitors |
|
Phase 3 |
|
|
|
9 |
|
Hormones |
|
Phase 3 |
|
|
|
10 |
|
Calcium, Dietary |
|
Phase 3 |
|
|
|
11 |
|
calcium channel blockers |
|
Phase 3 |
|
|
|
12 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 3 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
13 |
|
Calcium |
Nutraceutical |
Phase 3 |
|
7440-70-2 |
271 |
Synonyms:
Ca
Ca(2+)
Ca2+
Calcio
CALCIUM
Calcium element
|
CALCIUM ion
Calcium(2+)
Calcium, doubly charged positive ion
Calcium, elemental
Elemental calcium
Kalzium
|
|
14 |
|
Ropinirole |
Approved, Investigational |
Phase 2 |
|
91374-21-9 |
5095 |
Synonyms:
4-(2-(Di-N-propylamino)ethyl)-2(3H)-indolone
GlaxoSmithKline brand OF ropinirole hydrochloride
Requip
Requip®|SK&F-101468-A|SK&F-101468A
Ropinirol
Ropinirole
Ropinirole hydrochloride
Ropinirolum
|
Ropitor
SK And F 101468
SK And F-101,468
SK&F-101468
SK&F-101468A
SK&F-101468-A
SmithKline beecham brand OF ropinirole hydrochloride
|
|
15 |
|
Dopamine |
Approved |
Phase 2 |
|
62-31-7, 51-61-6 |
681 |
Synonyms:
2-(3,4-Dihydroxyphenyl)ethylamine
3,4 Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenylethylamine
3-Hydroxytyramine
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-AZANYLETHYL)BENZENE-1,2-DIOL
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL-279
CARBILEV
Deoxyepinephrine
Dopamin
Dopamina
DOPAMINE
DOPAMINE HCL
|
Dopamine hydrochloride
DOPAMIN-NATTERMAN
Dopaminum
Dopastat
Dophamine
DOPMIN
Dynatra
Hydrochloride, dopamine
Hydroxytyramin
Hydroxytyramine
Intropin
Medopa
NSC-169105
NSC-173182
Oxytyramine
PARCOPA
Revivan
SABAX DOPAMIN
SELECTAJET
SINEMET
|
|
16 |
|
Verapamil |
Approved |
Phase 2 |
|
152-11-4, 52-53-9 |
2520 |
Synonyms:
Akilen
Anpec
ANSYR
Ansyr®|CP-165331 / CP-16533-1|Securon®
Apo-verap
Arpamyl
Arpamyl LP
BERKATENS
CALAN
CALAN SR
Calaptin
Calaptin 240 SR
Calcan
Cardiabeltin
Cardiagutt
Cardibeltin
Cardioprotect
Caveril
Civicor
Civicor retard
Coraver
CORDILOX
CORDILOX I.V.
CORDILOX MR 240
Cordilox SR
Corpamil
COVERA
COVERA-HS
CP-165331
CP-16533-1
CP-165331 / CP-16533-1
CP-16533-1Calan
CP-165331Verapamil
D-365
D-365Iproveratril
delta-365
Dexverapamil
Dignover
Dilacoran
Dilacoran hta
Drosteakard
Durasoptin
Elthon
ETHIMIL MR 240
Falicard
Finoptin
Flamon
GEANGIN
HALF SECURON SR
Harteze
Hexasoptin
Hexasoptin retard
Hormitol
Hydrochloride, verapamil
Ikacor
Ikapress
Inselon
Iproveratril
Isoptimo
ISOPTIN
Isoptin retard
ISOPTIN SR
Isoptine
Isoptino
Isotopin
Izoptin
Jenapamil
Lekoptin
Lodixal
LU-20175
Magotiron
Manidon
Manidon retard
MANIDON SR
Novapamyl LP
Novo-veramil
|
NSC-272306NA
NSC-272366
NSC-657799
Nu-verap
Ormil
Praecicor
Quasar
RANVERA MR
Rapam
Robatelan
Sandoz brand OF verapamil
SECURON
SECURON IV
SECURON MID
SECURON SR
Tarka
UNIVER
Univex
Vasolan
Vasomil
Vasopten
Verabeta
Veracaps SR
Veracim
Veracor
Verahexal
Veraloc
Veramex
Veramil
Verapamil
Vérapamil
Verapamil [Usan:Ban:Inn]
Verapamil acis
Verapamil al
Verapamil atid
Verapamil basics
Verapamil ebewe
VERAPAMIL HCL
Verapamil henning
Verapamil hydrochloride
Verapamil injection
Verapamil MSD
Verapamil NM
Verapamil NM pharma
Verapamil nordic
Verapamil PB
Verapamil riker
Verapamil sandoz brand
Verapamil SR
Verapamil verla
Verapamil-abz
Verapamilo
Verapamilo [INN-Spanish]
Verapamilum
Verapamilum [INN-Latin]
Verapin
Verapress 240 SR
VERAPRESS MR 240
Veraptin
Verasal
Vera-sanorania
Verasifar
Veratensin
VERA-TIL SR
Verdilac
VERELAN
VERELAN PM
Verelan SR
Verexamil
Veroptinstada
Verpamil
VERTAB SR 240
Vetrimil
Vortac
ZOLVERA
|
|
17 |
|
Dopamine agonists |
|
Phase 2 |
|
|
|
18 |
|
Dopamine Agents |
|
Phase 2 |
|
|
|
19 |
|
Antiparkinson Agents |
|
Phase 2 |
|
|
|
20 |
|
Anti-Arrhythmia Agents |
|
Phase 2 |
|
|
|
21 |
|
Vasodilator Agents |
|
Phase 2 |
|
|
|
22 |
|
Levetiracetam |
Approved |
|
|
102767-28-2 |
441341 5284583 |
Synonyms:
AGB-101
alpha Ethyl 2 oxo 1 pyrrolidineacetamide
alpha-Ethyl-2-oxo-1-pyrrolidineacetamide
DESITREND
e Keppra
ELEPSIA XR
Etiracetam
Etiracetam, R isomer
Etiracetam, R-isomer
Etiracetam, S isomer
Etiracetam, S-isomer
Keppra
KEPPRA XR
Keppra®|Spritam®|UCB L059|UCB-L 059
LEVETIRACETAM
Levetiracetam [INN]
LEVETIRACETAM IN SODIUM CHLORIDE
|
Levetiracetame
Levetiracetamum
Levetiracetamum [INN-Latin]
Levitiracetam
MATEVER
N03AX14
R-Isomer etiracetam
S-Isomer etiracetam
SPRITAM
UCB brand OF levetiracetam
Ucb L059
Ucb L060
UCB-22059
Ucb-L059
UcbL060
Ucb-L060
|
|
23 |
|
Stiripentol |
Approved |
|
|
49763-96-4 |
5311454 |
Synonyms:
1-(1,3-BENZODIOXOL-5-YL)-4,4-DIMETHYL-1-PENTEN-3-OL
4,4-DIMETHYL-1-((3,4-METHYLENEDIOXY)PHENYL)-1-PENTEN-3-OL
BCX 2600
BCX-2600
BRN 1313047
|
DIACOMIT
ESTIRIPENTOL
STIRIPENTOL
STIRIPENTOLUM
|
|
Interventional clinical trials:
(show top 50)
(show all 59)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution |
Recruiting |
NCT05044819 |
Phase 4 |
Cannabidiol |
2 |
A Prospective Multi-Center Single-Arm Clinical Trial on Cognitive Effect of Cannabidiol (CBD-OS®) on Dravet Syndrome and Lennox-Gastaut Syndrome |
Unknown status |
NCT04611438 |
Phase 3 |
Cannabidiol |
3 |
An Exploratory, Pilot Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome: A Sub-study to the ZX008-1503 Open-Label Extension Trial |
Unknown status |
NCT03299842 |
Phase 3 |
ZX008 (Fenfluramine Hydrochloride) |
4 |
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |
Completed |
NCT02682927 |
Phase 3 |
ZX008 (Fenfluramine Hydrochloride);Matching Placebo |
5 |
A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome |
Completed |
NCT02091375 |
Phase 3 |
GWP42003-P 20 mg/kg/day Dose;Placebo control |
6 |
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome. |
Completed |
NCT02224703 |
Phase 3 |
GWP42003-P;Placebo Control |
7 |
A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome (Cohort 2) |
Completed |
NCT02926898 |
Phase 3 |
ZX008 (Fenfluramine Hydrochloride);Matching Placebo |
8 |
An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes. |
Completed |
NCT02224573 |
Phase 3 |
GWP42003-P |
9 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of Lorcaserin as Adjunctive Treatment in Subjects With Dravet Syndrome |
Recruiting |
NCT04572243 |
Phase 3 |
Placebo;Lorcaserin |
10 |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adult Subjects With Dravet Syndrome (DS) |
Recruiting |
NCT04940624 |
Phase 3 |
Soticlestat;Placebo |
11 |
A Phase 3, Prospective, Open-Label, Multisite, Extension of Phase 3 Studies To Assess the Long-Term Safety and Tolerability of Soticlestat as Adjunctive Therapy in Subjects With Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2) |
Recruiting |
NCT05163314 |
Phase 3 |
Soticlestat |
12 |
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome |
Active, not recruiting |
NCT02823145 |
Phase 3 |
ZX008 (Fenfluramine Hydrochloride) |
13 |
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy for Seizures in Patients With Rare Seizure Disorders Such as Epileptic Encephalopathies Including Dravet Syndrome and Lennox-Gastaut Syndrome |
Active, not recruiting |
NCT03936777 |
Phase 3 |
ZX008 (Fenfluramine Hydrochloride) |
14 |
Fenfluramine for the Treatment of Refractory Epilepsy in Adult Dravet Patients |
Not yet recruiting |
NCT05560282 |
Phase 3 |
Fenfluramine |
15 |
A Double-blind, Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Myoclonic Seizures Associated With Idiopathic Generalised Epilepsy |
Terminated |
NCT00693017 |
Phase 3 |
Zonisamide;Placebo |
16 |
Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome |
Terminated |
NCT02187809 |
Phase 3 |
Clobazam |
17 |
A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome |
Withdrawn |
NCT02318563 |
Phase 3 |
Cannabidiol Oral Solution;Placebo Solution |
18 |
Multi-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome |
Withdrawn |
NCT02174094 |
Phase 3 |
Clobazam;Placebo |
19 |
Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type |
Unknown status |
NCT00639119 |
Phase 2 |
Ropinirole |
20 |
Physical Exercise in Subjects With Juvenile Myoclonic Epilepsy Aged 15-50: A Randomized Controlled Trial |
Unknown status |
NCT01450423 |
Phase 2 |
|
21 |
A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome |
Completed |
NCT02758626 |
Phase 2 |
ataluren;Placebo |
22 |
A Double Blind, Placebo-controlled, Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome |
Completed |
NCT02091206 |
Phase 2 |
GWP42003-P 5 mg/kg/day Dose;Placebo control;GWP42003-P 10 mg/kg/day Dose;GWP42003-P 20 mg/kg/day Dose |
23 |
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies |
Completed |
NCT03650452 |
Phase 2 |
TAK-935;Placebo |
24 |
Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome |
Completed |
NCT01607073 |
Phase 2 |
Verapamil |
25 |
A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks |
Recruiting |
NCT05626634 |
Phase 2 |
LP352 |
26 |
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial) |
Recruiting |
NCT04462770 |
Phase 2 |
EPX-100 (Clemizole HCl);Placebo |
27 |
An Open-Label Study to Investigate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Antisense Oligonucleotide STK-001 in Children and Adolescents With Dravet Syndrome |
Recruiting |
NCT04442295 |
Phase 1, Phase 2 |
STK-001 - Single Ascending Doses;STK-001 - Multiple Ascending Doses |
28 |
Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies |
Recruiting |
NCT05364021 |
Phase 1, Phase 2 |
LP352;Placebo |
29 |
A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of Soticlestat (TAK-935) as Adjunctive Therapy in Subjects With Developmental Epileptic Encephalopathies Including Dravet Syndrome, Lennox Gastaut Syndrome, CDKL5 Deficiency Disorder, and Chromosome 15 Duplication Syndrome (ENDYMION 1) |
Active, not recruiting |
NCT03635073 |
Phase 2 |
Soticlestat |
30 |
An Open-Label Extension Study for Patients With Dravet Syndrome Who Previously Participated in Studies of STK-001 |
Enrolling by invitation |
NCT04740476 |
Phase 2 |
STK-001 |
31 |
ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children With SCN1A-Positive Dravet Syndrome |
Not yet recruiting |
NCT05419492 |
Phase 1, Phase 2 |
ETX101 |
32 |
The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children |
Terminated |
NCT02815540 |
Phase 1, Phase 2 |
Cannabidiol |
33 |
A Phase I, Placebo-Controlled, Double-Blind, 2-Period Study to Assess Safety and Pharmacokinetics of Escalating Single and Multiple Oral Doses of EPX-100 in Fasting Healthy Subjects and Following a High-Fat Meal |
Completed |
NCT04069689 |
Phase 1 |
EPX-100 (Clemizole Hydrochloride);Placebos |
34 |
An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome |
Completed |
NCT03467113 |
Phase 1 |
ZX008 0.2 to 0.8 mg/kg/day;Cannabidiol |
35 |
The Becoming of Children With Doose Syndrome |
Unknown status |
NCT04048213 |
|
|
36 |
ZX008 Expanded Access Protocol - Dravet Syndrome Treatment Plan |
Approved for marketing |
NCT03780127 |
|
Fenfluramine Hydrochloride |
37 |
Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome |
Approved for marketing |
NCT01983722 |
|
Stiripentol |
38 |
Treatment of Gait Disorders in Children With Dravet Syndrome |
Completed |
NCT03857451 |
|
|
39 |
Effects of Levetiracetam on Cortical Excitability in Humans |
Completed |
NCT00006191 |
|
|
40 |
Cardiac Arrhythmias in Dravet Syndrome: an Observational, International, Multicentre Study |
Completed |
NCT02415686 |
|
|
41 |
Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population |
Completed |
NCT02229032 |
|
|
42 |
Biology of Juvenile Myoclonic Epilepsy |
Recruiting |
NCT03400371 |
|
|
43 |
Transcranial Magnetic Stimulation to Measure Cortical Excitability in Dravet Syndrome |
Recruiting |
NCT04614506 |
|
|
44 |
Genetics of Epilepsy and Related Disorders |
Recruiting |
NCT01858285 |
|
|
45 |
A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives |
Recruiting |
NCT05635266 |
|
|
46 |
Retrospective Non-interventional Study of Stiripentol Use in Dravet Patients in the USA |
Recruiting |
NCT05544058 |
|
|
47 |
Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome |
Recruiting |
NCT05472389 |
|
|
48 |
Neuronal Excitability of Hyperpolarization-activated Cyclic Nucleotide-gated (HCN1) Channel Mutations in Dravet Syndrome |
Recruiting |
NCT02896608 |
|
|
49 |
ENVISION: Natural History Study of Infants and Children With Developmental and Epileptic Encephalopathies |
Active, not recruiting |
NCT04537832 |
|
|
50 |
Extended Access Program and Retrospective Chart Review for Lorcaserin in Dravet Syndrome and Other Refractory Epilepsies |
Available |
NCT04457687 |
|
Lorcaserin |
Inferred drug relations via
UMLS
71
/
NDF-RT
50
:
|